Viromed Medical AG Achieves Milestone with Ex-Vivo Lung Study

Viromed Medical AG, a leader in cold plasma technology, announced a significant advancement in medical research with the upcoming ex-vivo lung study in collaboration with Saarland University and Hannover Medical School. Slated for February and March 2026, the study aims to further develop Viromed's technology platform and expedite research and approval processes.

This ground-breaking study features an isolated lung model with 95% genetic similarity to humans, allowing detailed analysis over four to six weeks. The model, previously validated, offers precise measurements to potentially replace human studies. The ex-vivo procedure also reduces time and regulatory burdens, eliminating the need for animal or human trials.

Viromed's ex-vivo study, integral to pharmaceutical and medical advancements, is a step towards faster approval of treatments like PulmoPlas®, promising shorter research phases and enhanced data quality.